Why the study?
Does brain natriuretic peptide have a significant diagnostic value in subclinical peripheral arterial disease in type 2 diabetic patients?
Does brain natriuretic peptide have a significant diagnostic value in subclinical peripheral arterial disease in type 2 diabetic patients?
BNP may serve as a highly specific but poorly sensitive biomarker for screening peripheral arterial disease in patients with type 2 diabetes.
Peripheral arterial disease (PAD) is a serious complication of diabetes mellitus (DM); it is also correlated with increase in the morbidity and mortality in diabetics owing to cardiovascular disease. Ankle–brachial index (ABI) is an established method to detect PAD. This is a cross-sectional study to detect brain natriuretic peptide (BNP) level in patient with type-2 DM with PAD using ABI. This study revealed 11 patients diagnosed with low ABI. Patients with low ABI showed statistical significance regarding mean age ( P =0.038), duration of DM ( P =0.004), concentration of glycated hemoglobin ( P =0.044), BNP ( P =0.013), and microalbuminurea ( P =0.007). Moreover, patients with low ABI were significantly associated with nephropathy ( P =0.001) and retinopathy ( P =0.007). BNP at cutoff value of 360 pg/ml had sensitivity and specificity of 27.27 and 95.9, respectively. The BNP level was negatively correlated with the ABI ( r = –0.183, P =0.162). BNP showed statistical significance with fasting blood sugar, postprandial glucose, nephropathy, retinopathy, and albumin/creatinine ratio in urine. BNP is a potential and a promising biomarker for PAD screening in patients with type-2 DM.
No takes yet. Share an insight, caveat, or question.
Fahmy et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: